Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol
| Autor: | Ulrike eKoehl, Claudia eBrehm, Sabine eHuenecke, Stephan eKloess, Melanie eBremm, Stefanie Yvonne eZimmermann, Evelyn eUllrich, Jan eSoerensen, Andrea eQuaiser, Stephanie eErben, Claudia eWunram, Tanja eGardlowski, Eileen eAuth, Torsten eTonn, Chritian eSeidl, Sandrine eMeyer-Monard, Martin eStern, Jakob ePassweg, Thomas eKlingebiel, Peter eBader, Dirk eSchwabe, Ruth eEsser |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: | |
| Zdroj: | Frontiers in Oncology, Vol 3 (2013) |
| Druh dokumentu: | article |
| ISSN: | 2234-943X 34924019 |
| DOI: | 10.3389/fonc.2013.00118 |
| Popis: | Allogeneic Natural Killer (NK) cells are used for adoptive immunotherapy after stem cell transplantation. In order to overcome technical limitations in NK cell purification and activation, the following study investigates the impact of different variables on NK cell recovery, cytotoxicity and T cell depletion during GMP-grade NK cell selection. 40 NK cell products were derived from 54 unstimulated donor leukaphereses using immunomagnetic CD3 T-cell depletion, followed by a CD56 cell enrichment step. For T cell depletion, either the depletion 2.1 program in single or double procedure (D2.1 1depl, n=18; D2.1 2depl, n=13) or the faster depletion 3.1 (D3.1, n=9) was used on the CliniMACS instrument. 17 purified NK cell products were activated in vitro by IL-2 for 12 days. The whole process resulted in a median number of 7.59x10e8 CD56+CD3- cells with both purity and viability of 94%, respectively. The T-cell depletion was significantly better using D2.1 1depl/2depl compared to D3.1 (log 4.6/log 4.9 vs. log 3.7; p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|